SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments

SwanBio have released a press release about their AMN natural history study using wearable technology – with the data collected to provide insights for future first-in-human study of SBT101, AAV-based gene therapy for AMN.

To read the press release: https://swanbiotx.com/investors-and-media/swanbio-presents-design-of-innovative-natural-history-study-aimed-to-evolve-understanding-of-adrenomyeloneuropathy-and-inform-future-treatments/